Glucagon News and Research

RSS
TransTech Pharma, High Point receive $1.96 million grants under QTDP program

TransTech Pharma, High Point receive $1.96 million grants under QTDP program

FDA issues complete response letter for BYDUREON NDA

FDA issues complete response letter for BYDUREON NDA

UT Southwestern initiates study on hormone leptin for people with type 1 diabetes

UT Southwestern initiates study on hormone leptin for people with type 1 diabetes

Australian reimbursement committee is set to consider Novo Nordisk's type 2 diabetes treatment

Australian reimbursement committee is set to consider Novo Nordisk's type 2 diabetes treatment

Improper biological clocks tend to develop diabetes, obesity: Research

Improper biological clocks tend to develop diabetes, obesity: Research

TransPharma Medical completes ViaDerm-GLP1 agonist Phase 1a trial for type II diabetes

TransPharma Medical completes ViaDerm-GLP1 agonist Phase 1a trial for type II diabetes

Isis second-quarter pro forma net operating loss increases to $15.5 million

Isis second-quarter pro forma net operating loss increases to $15.5 million

Artificial pancreas holds promise for treating Type 1 diabetes

Artificial pancreas holds promise for treating Type 1 diabetes

Marcadia, Eli Lilly sign development, license agreement for short-acting glucagon program

Marcadia, Eli Lilly sign development, license agreement for short-acting glucagon program

Roche reports results of 5 taspoglutide Phase III studies for type 2 diabetes at 70th ADA

Roche reports results of 5 taspoglutide Phase III studies for type 2 diabetes at 70th ADA

Zydus Cadila receives DCGI approval to initiate Phase I clinical trial for ZYOG1

Zydus Cadila receives DCGI approval to initiate Phase I clinical trial for ZYOG1

Artificial pancreas system reduces risk of nocturnal hypoglycemia

Artificial pancreas system reduces risk of nocturnal hypoglycemia

DURATION-4 study tests superiority of BYDUREON as compared to other type 2 diabetes medications

DURATION-4 study tests superiority of BYDUREON as compared to other type 2 diabetes medications

Roche implements risk mitigation plan in taspoglutide Phase III programme

Roche implements risk mitigation plan in taspoglutide Phase III programme

Hormone that helps regulate blood sugar levels may influence sensitivity to sweet-tasting foods: Study

Hormone that helps regulate blood sugar levels may influence sensitivity to sweet-tasting foods: Study

Emisphere Technologies first-quarter net loss increases to $18.5 million

Emisphere Technologies first-quarter net loss increases to $18.5 million

FDA assigns BYDUREON new PDUFA action date of October 22, 2010

FDA assigns BYDUREON new PDUFA action date of October 22, 2010

Scripps Research Institute awarded grant to design assays for exploring potential target for obesity, Type 2 diabetes

Scripps Research Institute awarded grant to design assays for exploring potential target for obesity, Type 2 diabetes

Roche announces results of phase III T-emerge 3 study of taspoglutide in diabetics

Roche announces results of phase III T-emerge 3 study of taspoglutide in diabetics

Amylin, Eli Lilly and Alkermes reply to FDA complete response letter for BYDUREON NDA

Amylin, Eli Lilly and Alkermes reply to FDA complete response letter for BYDUREON NDA